Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill amends the Public Health Service Act and related statutes to require that amounts paid by or on behalf of an enrollee — including financial assistance from nonprofit organizations and prescription drug manufacturers — be counted toward deductibles, coinsurance, copayments, and out-of-pocket limits. It adds conforming changes to the Affordable Care Act and creates a safe harbor so counting such assistance does not disqualify high-deductible health plans for HSA purposes.
Liberals emphasize patient affordability and blocking accumulator policies
Narrow, nonbudgetary healthcare change with stakeholder opposition likely; could attract bipartisan cosponsors but faces insurer resistance.
This bill amends the Public Health Service Act and related statutes to require that amounts paid by or on behalf of an enrollee — including financial assistance from nonprofit organizations and prescription drug manufacturers — be counted toward deductibles, coinsurance, copayments, and out-of-pocket limits.
It adds conforming changes to the Affordable Care Act and creates a safe harbor so counting such assistance does not disqualify high-deductible health plans for HSA purposes.
The changes explicitly cover specialty drugs and drugs subject to utilization management, do not restrict utilization management tools, and apply to plan years beginning on or after January 1, 2026.
Targeted, administrable change that could win bipartisan backers, but significant industry pushback and legislative barriers lower probability.
How solid the drafting looks.
Liberals emphasize patient affordability and blocking accumulator policies
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize patient affordability and blocking accumulator policies
Likely broadly supportive because the bill reduces patient cost-sharing and counters copay accumulator effects, improving affordability for people with high drug costs.
However, some would want additional measures addressing high list prices and ensuring manufacturer assistance doesn’t substitute for pricing reform.
Any concerns about unintended incentives would be characterized as speculative without explicit offsets in the bill.
Generally favorable to the patient-affordability goal but cautious about unintended market incentives and fiscal effects.
Support would likely hinge on monitoring impacts on premiums, insurer administrative burdens, and whether manufacturer behavior changes list prices.
Likely skeptical or opposed because the bill mandates insurer counting of third-party payments and explicitly includes manufacturer assistance, which could reduce market pressure to lower drug list prices.
Concerns include federal overreach, increased premiums, and undermining private market incentives.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Targeted, administrable change that could win bipartisan backers, but significant industry pushback and legislative barriers lower probability.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize patient affordability and blocking accumulator policies
Targeted, administrable change that could win bipartisan backers, but significant industry pushback and legislative barriers lower probabil…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for HELP Copays Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.